Clinical Trial Highlights

• Results of the International Scleroderma Renal Crisis Survey
• Apolipoprotein G1 and G2 Variants May Partially Explain a Higher Prevalence of Lupus-Nephritis ESRD in African Americans
• Genetic Variations Do Not Account for Variable Response to Mycophenolate Mofetil in Lupus Nephritis
• Cardiac Neonatal Lupus: Long-Term Data Show More Problems with Aging
• Fluorinated Steroids in Cardiac Neonatal Lupus Do Not Impact Survival
• Tocilizumab Significantly Reduces Flares in Polyarticular Juvenile Idiopathic Arthritis
• Autoantibodies Predict Treatment Response to Rituximab in Myositis
• The Risk of Lymphoma in Patients Receiving Anti-TNF Therapy for RA: Results from the BSR Biologics Register
• Head-to-Head Biologics Trial Shows No Difference between Abatacept and Adalimumab
• Etanercept Proves Clinically Superior to Discontinuation: Results from the DOSERA Trial
• IMPROVED: Final Study Results of Combination Treatment in Patients with Early RA and UA
• Short- and Long-Term Efficacy of Tofacitinib in the Treatment of Patients with RA and an Inadequate Response to TNF Inhibitors
• SC Tocilizumab Reduces RA Disease Activity When Used with DMARDs
• Apremilastin Patients with Psoriatic Arthritis: Results of the PALACE-1 Trial
• The SEKOIA Trial: A Structural and Symptomatic Efficacy
• Effects of Odanacatib in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
• Anti-TGFβ Inhibits TGFβ-Regulated Gene Expression in Skin and Is Associated with a Rapid Decline in Skin Score
• Inefficacy of Hydroxychoroquine in Primary Sjögren's Syndrome: Results of the JOQUER Trial